HealthcareServices

Choroidal Neovascularization Market Insights Report: Opportunities and Drivers 2030

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the choroidal neovascularization market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Choroidal Neovascularization Market between 2026 and 2030?

The choroidal neovascularization market size has demonstrated strong growth in recent years. It is anticipated to increase from $4.18 billion in 2025 to $4.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This expansion observed during the historic period can be attributed to factors such as the increasing prevalence of age-related macular degeneration, rising diabetic eye disease cases, the expansion of ophthalmology clinics, the availability of anti-angiogenic drugs, and improved retinal diagnostic capabilities.

The choroidal neovascularization market size is anticipated to experience robust expansion over the next few years. It is projected to reach $5.99 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. This growth during the forecast period can be attributed to an increasing aging population, a rising emphasis on early ophthalmic intervention, the expansion of combination therapy approaches, growing investments in retinal disease research, and the increasing adoption of personalized treatment protocols. Significant trends for the forecast period include the increasing uptake of anti-VEGF therapies, the rising use of treat-and-extend regimens, a growing demand for early CNV diagnosis, the expansion of advanced retinal imaging techniques, and an enhanced focus on vision preservation therapies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

Which Drivers Are Expected To Impact The Choroidal Neovascularization Market During The Forecast Period?

The growing incidence of age-related macular degeneration (AMD) is anticipated to drive the expansion of the choroidal neovascularization (CNV) market moving ahead. Age-related macular degeneration (AMD) refers to an ocular condition that progressively impairs the macula, resulting in the loss of central vision, predominantly among elderly individuals. This increasing prevalence of age-related macular degeneration (AMD) stems from factors such as an aging demographic, extended life expectancy, shifts in lifestyle, genetic predispositions, and heightened vulnerability to environmental hazards. Choroidal neovascularization (CNV) plays a role in patients with age-related macular degeneration (AMD) by fostering the onset of wet AMD, where the proliferation of aberrant blood vessels under the retina causes vision decline, necessitating advanced therapeutic interventions like anti-VEGF therapy to control choroidal neovascularization (CNV) and impede the advancement of age-related macular degeneration (AMD), thereby aiming to safeguard central vision for those impacted. For illustration, the UHN Foundation, Canada-Based official fundraising arm, reported that by 2025, age-related macular degeneration (AMD) stands as the principal reason for considerable, permanent vision impairment in persons exceeding 50 years of age. Globally, it currently impacts more than 200 million individuals, with projections indicating an increase to 288 million by 2040. Consequently, the expanding occurrence of age-related macular degeneration is fueling the expansion of the choroidal neovascularization market.

Which Segments Are Driving Activity In The Choroidal Neovascularization Market?

The choroidal neovascularization market covered in this report is segmented –

1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications

3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral

4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:

1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium

2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy

3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT

4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF

5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen

6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections

7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen

8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

How Are New Market Trends Shaping The Landscape Of The Choroidal Neovascularization Market?

Leading companies operating in the choroidal neovascularization market are concentrating on developing innovative treatments, such as photodynamic therapy, to equip eye care professionals with precise and efficient options that enhance patient outcomes and treatment delivery. Photodynamic therapy (PDT) is a medical procedure utilizing a photosensitizing agent activated by light to specifically target and eliminate abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a Canada-based healthcare company, and Modulight, a Finland-based biomedical company, announced the ML6710i photodynamic laser, which gained approval from the Food and Drug Administration, a US-based federal agency. This therapy is approved for use with Bausch + Lomb’s VISUDYNE therapy, specifically designed to address choroidal neovascularization stemming from age-related macular degeneration (AMD). This modern, mobile ophthalmic laser provides a targeted strategy for treating abnormal blood vessels in the eye, contributing to the prevention of further disease progression and the preservation of vision.

Which Major Firms Are Strengthening Their Position In The Choroidal Neovascularization Market?

Major companies operating in the choroidal neovascularization market are Roche Holding AG, Regeneron Pharmaceuticals Incorporated, Bayer Aktiengesellschaft, Novartis AG, Apellis Pharmaceuticals Incorporated, Kodiak Sciences Incorporated, Adverum Biotechnologies Incorporated, Clearside Biomedical Incorporated, Graybug Vision Incorporated, Outlook Therapeutics Incorporated, Oxurion NV, 4D Molecular Therapeutics Incorporated, Opthea Limited, Eyepoint Pharmaceuticals Incorporated, Ocular Therapeutix Incorporated, OcuTerra Therapeutics Incorporated, Ocuphire Pharma Incorporated, Kubota Vision Incorporated, Amgen Incorporated, Coherus BioSciences Incorporated, Formycon AG, Alimera Sciences Incorporated, Neurotech Pharmaceuticals Incorporated, Alkeus Pharmaceuticals Incorporated, Aerie Pharmaceuticals Incorporated, Acucela Incorporated

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

Which Regions Are Poised For Strategic Growth In The Choroidal Neovascularization Market?

North America was the largest region in the choroidal neovascularization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Choroidal Neovascularization Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

Browse Through More Reports Similar to the Global Choroidal Neovascularization Market 2026, By The Business Research Company

Ocular Hypertension Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/ocular-hypertension-treatment-global-market-report

Intravascular Ultrasound Market Report 2026

https://www.thebusinessresearchcompany.com/report/intravascular-ultrasound-global-market-report

Vascular Imaging Market Report 2026

https://www.thebusinessresearchcompany.com/report/vascular-imaging-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795